Correspondence 0001493152-23-024573 from ZyVersa Therapeutics, Inc. (ZVSA)

ZyVersa Therapeutics, Inc.
Date: July 14, 2023 · CIK: 0001859007 · Accession: 0001493152-23-024573

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-272657

Date

July 14, 2023

Author

ZYVERSA

Form

CORRESP

Company

ZyVersa Therapeutics, Inc.

Letter

VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Washington, D.C. 20549 Re: ZyVersa Therapeutics, Inc. (the “Company”) Registration Statement on Form S-1, as amended File No. 333-272657 (the “Registration Statement”)

Dear Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement be declared effective by the Securities and Exchange Commission at 5:00 p.m., Eastern Time on July 17, 2023 or as soon as practicable thereafter.

Please call Jack Hogoboom of Lowenstein Sandler LLP at (973) 587-2382 to confirm the effectiveness of the Registration Statement or with any questions.

[Signature Page Follows]

Sincerely,
ZYVERSA
THERAPEUTICS, INC.

Show Raw Text

CORRESP
1
filename1.htm

ZYVERSA
THERAPEUTICS, INC.

2200
N. Commerce Parkway, Suite 208

Weston,
FL 33326

July
14, 2023

VIA
EDGAR

United
States Securities and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
D.C. 20549

    Re:
    ZyVersa
    Therapeutics, Inc. (the “Company”)

    Registration
    Statement on Form S-1, as amended

    File
    No. 333-272657 (the “Registration Statement”)

Dear
Ladies and Gentlemen:

Pursuant
to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement
be declared effective by the Securities and Exchange Commission at 5:00 p.m., Eastern Time on July 17, 2023 or as soon as practicable
thereafter.

Please
call Jack Hogoboom of Lowenstein Sandler LLP at (973) 587-2382 to confirm the effectiveness of the Registration Statement or with any
questions.

[Signature
Page Follows]

    Sincerely,

    ZYVERSA
    THERAPEUTICS, INC.

    By:

    /s/
    Stephen C. Glover

    Name:

    Stephen
    C. Glover

    Title:

    Chief
    Executive Officer

SecProbe.io